p53 as a specific prognostic factor in triple-negative breast cancer.

Primary tabs

Average: 5 (1 vote)
Other Key Words:: 
Therapeutic intervention: 
Publication type: 

Jpn J Clin Oncol. 2009 Apr;39(4):217-24. Epub 2009 Mar 20.
p53 as a specific prognostic factor in triple-negative breast cancer.Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, Kim JS, Jung SS.Department of Surgery, Catholic University of Korea, Seoul, Republic of KoreaOBJECTIVE:
A recent suggestion is that the predictive value of a single biomarker
may rely on the genetic background on the tumor and that different
breast cancer subgroups may have different predictive markers of
response to chemotherapy. The prognostic value of p53 in the outcome of
adjuvant anthracycline-containing chemotherapy was evaluated according
to molecular subclasses defined using the expression of estrogen
receptor, progesterone receptor and human epidermal growth factor
receptor 2.
METHODS: Subjects were patients (n = 135) with invasive
ductal carcinoma treated with adjuvant anthracycline-based chemotherapy
between 1994 and 2000 in our hospital. Clinico-pathological features
were reviewed by retrospective examination of medical records.
Overall survival rate was not independently predictive by p53 status (P
= 0.182). However, in triple-negative cases, there was statistically
significant survival difference (P = 0.034) and no statistically
significant difference (P = 0.783) in non-triple-negative cases by p53
status. In the Cox proportional hazard analysis, p53 was also strongly
predictive for relapse-free survival (P = 0.013) and overall survival
(P = 0.049) in triple-negative patients.
CONCLUSIONS: p53 status could
be a specific prognostic factor in triple-negative breast cancer
patients treated by adjuvant anthracycline-based regimen. When p53 is
positive in triple-negative breast cancer, we could expect poor
survival, prompting aggressive or alternative treatment.